Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001576419-25-000599·4D Molecular Therapeutics, Inc.
Schedule 13G ownership disclosure
4D Molecular Therapeutics Inc
Common Stock · CUSIP: 35104E100
Event date: 2025-03-31
- Filing-level shares
- 3,615,316
- Percent of class
- 7.8%
- BlackRock, Inc.
Shares: 3,615,316 · Class: 7.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001576419-25-000599
- Form type
- SCHEDULE 13G/A
- Filer
- 4D Molecular Therapeutics, Inc.
- CIK
- CIK 1650648
- Filed
- Apr 17, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership